Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 135 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06456528RecruitingPhase 2/Phase 3
Study of QL0911 for low platelets caused by chemo
This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.
HarbinAges 18–75 - NCT06449651RecruitingPhase 3
Nipocalimab to prevent low platelets in newborns
This study tests a medicine called nipocalimab for pregnant women whose babies are at risk of a bleeding condition called FNAIT. The medicine may help prevent low platelet counts and serious bleeding in the newborn.
LeuvenAges 18–45 - NCT06223607Recruiting
Dual antiplatelet therapy in patients with low platelets
This trial looks at whether taking two blood thinners (aspirin plus clopidogrel or ticagrelor) after a heart stent procedure is safe and effective for people who already have low platelet counts. It may help doctors decide the best treatment for you if you have both low platelets and a stent.
Dallas, TexasAges 18 years+ - NCT06168851RecruitingPhase 2
Anti-CD38 antibody for children with chronic ITP
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 6–17 - NCT06107582Recruiting
Long-term study of children with immune thrombocytopenia
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
TianjinAges 6–17 - NCT05599880RecruitingPhase 2
Bortezomib for adults with hard-to-treat immune low platelets
This Phase 2 trial tests whether bortezomib can safely increase platelet counts in adults with immune thrombocytopenia (ITP) that keeps coming back or doesn’t respond to standard treatments. It’s for people with very low platelets who still need treatment despite prior medicines.
Guri-siAges 19 years+ - NCT05255003RecruitingPhase 4
Anticoagulation options for low platelets with cancer blood clots
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
Edmonton, AlbertaAges 18 years+ - NCT02877706Recruiting
Registry study for newly diagnosed ITP or AIHA
This study is a registry that collects medical information from adults who are newly diagnosed with immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA), or who are starting a treatment called fosfamatinib. It can help doctors understand these conditions better and improve future care.
ToulouseAges 18 years+ - NCT04518475RecruitingPhase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
TianjinAges 18–60 - NCT07877727Recruiting
Rare blood disease network for better care
This study creates a national network to collect health information and samples from people with certain rare blood diseases. The goal is to improve treatment and understand these conditions better.
AvellinoAges 4 weeks–65 years - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT04968899RecruitingPhase 3
IgG IV plus prednisone versus high-dose dexamethasone for ITP
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
CréteilAges 18–80 - NCT05694325Recruiting
Studying biologic features in adults with newly diagnosed ITP
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
BolognaAges 18 years+ - NCT06478537RecruitingPhase 2
Hetrombopag for Immune Tolerance in ITP After Platelet Recovery
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
Beijing, Beijing MunicipalityAges 18–50 - NCT06479291Recruiting
HCQ plus TPO-RA for ANA positive ITP
This trial tests if combining two medicines (HCQ and a TPO-RA) can help people with a type of low platelet count called ITP who also have a positive ANA blood test. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT06479304Recruiting
Hydroxychloroquine plus prednisone for ANA-positive ITP
This study tests whether a combination of hydroxychloroquine (HCQ) and prednisone (a steroid) is safe and effective for treating immune thrombocytopenia (ITP) in people who have a positive ANA blood test. It may be an option for those with low platelets and bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT06479317Recruiting
Combining hydroxychloroquine and dexamethasone for ITP with positive ANA
This trial tests if adding hydroxychloroquine (HCQ) to the steroid dexamethasone (DEX) works better than dexamethasone alone for adults with immune thrombocytopenia (ITP) who have a positive antinuclear antibody (ANA) blood test. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Shanghai, Shanghai MunicipalityAges 15–75 - NCT06556888Recruiting
ITP observatory in the Brest region
This study is an observatory in the Brest region of France that collects information from people with ITP (immune thrombocytopenia) to better understand the condition. You may be eligible if you have ITP and are willing to share your experience.
Brest, Brittany RegionAges Any age - NCT07757789Recruiting
Platelet changes in antiphospholipid syndrome
This study looks at how platelet counts change over time in people with antiphospholipid syndrome (APS), a condition that can cause blood clots and pregnancy problems. It may help doctors better understand and manage low platelets in APS patients.
Al Khārjah, Kharga OasisAges 18 years+ - NCT07710248RecruitingPhase 2
Safety of SG301-SC in adults with ITP
This study tests a new injection called SG301-SC for people with primary immune thrombocytopenia (ITP) whose platelet counts stay low even after standard treatments. The goal is to see if it is safe and helps raise platelets, reducing bleeding risk.
Fuzhou, FujianAges 18–75 - NCT07616349Recruiting
Testing Blood Clotting in Pregnant Women With Low Platelets
This study tests a machine called ROTEM Sigma that measures how well your blood clots, specifically in pregnant women who have or may have low platelet counts (cells that help blood clot). The goal is to help doctors better predict bleeding problems during or after delivery.
MadridAges 18 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT06787989RecruitingPhase 1
BCMA-CD19 car T cell therapy for immune thrombocytopenia with autoimmune diseases
This trial tests a personalized cell therapy (CAR T cells) that targets two proteins (BCMA and CD19) on immune cells to treat low platelet counts (thrombocytopenia) that haven't improved with other treatments and are linked to autoimmune diseases like lupus or Sjogren's. The goal is to see if this therapy can safely raise your platelet levels and reduce bleeding symptoms.
Chengdu, SichuanAges 18–60
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 135 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.